Company Overview and News

 
The Top IPOs From This Week

2h 247wallst
With the markets at all-time highs, it is prime season for initial public offerings (IPOs) and companies can get more bang for their buck. There were a couple major IPOs this past week that lived up to the hype and then some, and one that floundered.
EB DB BNPQY LLY BNPQF BNPZY XYF ELAN MS

6
Software provider Solarwinds files for IPO

16h marketwatch
Solarwinds Corp. has filed for an initial public offering, seeking to sell up to $500 million worth of shares, according to a filing. The Austin, Texas-based IT infrastructure software provider went public in 2009, and it was acquired and taken private by private-equity firms Silver Lake Partners and Thoma Bravo seven years later. "Today, we are a very different company than we were in early 2016," having added more products recently, the company said in its prospectus.
SWI DTK MS

 
Smiths Group PLC (SMGKF) CEO Andy Smith on Q4 2018 Results - Earnings Call Transcript

17h seekingalpha
Good morning, everybody. Thank you very much for coming, and welcome to the Smiths Group presentation of our annual results. My name is Jemma Spalton, and I'm the Director of Investor Relations. Just a few housekeeping points before we get started. We're not expecting a fire drill, so if the alarms do sound, please exit through the fire exits to the left and right. And I'd also be grateful if you are able to spend a couple of moments just reading and digesting our disclaimer slide.
SMIN DB SMGZY SMGKF ICUI MS

 
argenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million

18h globenewswire
Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the closing of its public offering in the United States and an offering in Europe only to qualified investors (within the meaning of Directive 2003/71/EC, as amended) (the Offering) of 3,475,000 American Depositary Shares (ADSs) at a price to the public of $86.
MS BR

 
Defensive Goldman Sachs or bullish Morgan Stanley?

20h thehindubusinessline
Two diametrically opposite reports from premier financial institutions on the Indian market have left many retail investors perplexed. While one changed its bullish stance (since 2014) to neutral, the other has maintained its optimism on Indian markets.
MS

39
Top Analyst Reports for Netflix, EOG Resources & Simon Property Group

21h zacks - 1
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), EOG Resources (EOG) and Simon Property Group (SPG). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
WFCNP TXN NFLX MS WFC UNP EOG S SPG

 
Sky auction brings fees bonanza for City advisers

22h telegraph.co.uk
More than half a billion pounds in fees for bankers, lawyers, accountants and public relations firms are at stake in the next 24 hours as Comcast takes on with 21st Century Fox and Disney in the final battle for Sky.
DB PJT MS

 
Wall Street analysts are worried about a memory chip downturn as Micron shares keep falling

2018-09-21 cnbc
Micron confirmed investors' worst fears, saying PC processor shortages are hurting demand for its memory chips.
MS

 
Deals Buzz: Morgan Stanley to invest more in India

2018-09-21 livemint
Mint brings to you your dose of the top deals news reported from newsrooms across the country.
VED DB 0700 MS

 
Prime Minister Alexis Tsipras’ Contacts in New York

2018-09-21 thenationalherald
Prime Minister Alexis Tsipras will visit New York to participate in the proceedings of the UN General Assembly. He will be accompanied by Foreign Minister Nikos Kotzias, Digital Policy Minister Nikos Pappas, Alternate Finance Minister Giorgos Chouliarakis and deputy minister to the prime minister Dimitris Liakos.
MS

15
United Natural Foods, Inc. (UNFI) CEO Steve Spinner on Q4 2018 Results - Earnings Call Transcript

2018-09-21 seekingalpha
United Natural Foods, Inc. (NASDAQ:UNFI) Q4 2018 Earnings Conference Call September 20, 2018 5:00 AM ET
WFCNP DB MS WFC SVU UNFI

 
Separating Good From Bad Emerging Market Exposure

2018-09-21 seekingalpha
As pioneers of Modern Alpha™ strategies and currency hedging, WisdomTree has been at the forefront of providing smarter exposure to investors. Our head of Research, Jeremy Schwartz, recently wrote about managing currency risk in our newly launched Emerging Market (EM) multifactor strategy. This comes at a time when EM currencies have been under immense pressure due to trade concerns, sanctions and a host of other global macro-related issues.
MS

 
What Amazon-More deal means for offline retail in India

2018-09-21 livemint
New Delhi: Amazon has been making inroads into India’s offline space since last year, much like in the US, through partnerships and acquisitions of well-known consumer brands and start-ups. Mint analyses how it is trying to disrupt the offline retail space for a bigger slice of the pie.
500096 DABUR 532638 MS DBRQY SHOPERSTOP

16
Adobe to buy marketing software firm Marketo for $4.75 billion

2018-09-21 moneycontrol
Adobe Systems Inc on Thursday agreed to buy Marketo Inc for $4.75 billion from private equity firm Vista Equity Partners Management, adding heft to its cloud-based digital marketing business.
SAPGF MKTO ADBE SAP OCLCF MSFT MS ORCL

4
Samsung Is Planning to Lower Chip Growth to Maintain Prices

2018-09-21 theedgemarkets
(Sept 21): Samsung Electronics Co. is planning to curtail growth in memory chip output next year to keep supplies tight amid an expected slowing in demand, according to people briefed on the matter.
LRCX HXSCF BC94 WDC SMSN MU AMAT AAPL MS SMSD HXSCL

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 61747S504